Amgen partners with AstraZeneca to co-develop and commercialize five Amgen mAbs from its inflammation portfolio, including brodalumab

Amgen Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

AstraZeneca plc

U.K. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced